{"nctId":"NCT02201901","briefTitle":"Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis","startDateStruct":{"date":"2014-07"},"conditions":["Hepatitis C Virus Infection"],"count":268,"armGroups":[{"label":"SOF/VEL 12 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL"]},{"label":"SOF/VEL+RBV 12 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL","Drug: RBV"]},{"label":"SOF/VEL 24 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL"]}],"interventions":[{"name":"SOF/VEL","otherNames":["GS-7977/GS-5816","Epclusa®"]},{"name":"RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* HCV RNA \\> 10\\^4 IU/mL at screening\n* Chronic HCV infection (≥ 6 months)\n* Confirmed CPT class B (7-9) at screening\n\nExclusion Criteria:\n\n* Current or prior history of solid organ transplantation, significant pulmonary disease, significant cardiac disease, or porphyria\n* Inability to exclude hepatocellular carcinoma (HCC) by imaging within 6 months of baseline/Day 1\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n* Screening ECG with clinically significant abnormalities\n* Prior exposure to SOF or any other nucleotide analogue HCV nonstructural protein 5B (NS5B) inhibitor or any HCV NS5A inhibitor\n* Laboratory results outside of acceptable ranges at screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"94.3","spread":null},{"groupId":"OG002","value":"87.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"16.1","spread":null},{"groupId":"OG002","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null},{"groupId":"OG001","value":"95.4","spread":null},{"groupId":"OG002","value":"90.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"94.3","spread":null},{"groupId":"OG002","value":"87.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"14.9","spread":null},{"groupId":"OG002","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.4","spread":null},{"groupId":"OG001","value":"49.4","spread":null},{"groupId":"OG002","value":"39.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.1","spread":null},{"groupId":"OG001","value":"80.5","spread":null},{"groupId":"OG002","value":"91.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"97.6","spread":null},{"groupId":"OG002","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"98.8","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.8","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.8","spread":null},{"groupId":"OG002","value":"97.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"97.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.51","spread":"0.652"},{"groupId":"OG001","value":"-3.63","spread":"0.691"},{"groupId":"OG002","value":"-3.72","spread":"0.680"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.24","spread":"0.677"},{"groupId":"OG001","value":"-4.17","spread":"0.647"},{"groupId":"OG002","value":"-4.38","spread":"0.669"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.78","spread":"0.549"},{"groupId":"OG001","value":"-4.58","spread":"0.568"},{"groupId":"OG002","value":"-4.70","spread":"0.613"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.87","spread":"0.536"},{"groupId":"OG001","value":"-4.68","spread":"0.607"},{"groupId":"OG002","value":"-4.74","spread":"0.630"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.87","spread":"0.536"},{"groupId":"OG001","value":"-4.68","spread":"0.622"},{"groupId":"OG002","value":"-4.76","spread":"0.613"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.87","spread":"0.536"},{"groupId":"OG001","value":"-4.67","spread":"0.634"},{"groupId":"OG002","value":"-4.76","spread":"0.613"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.87","spread":"0.536"},{"groupId":"OG001","value":"-4.68","spread":"0.624"},{"groupId":"OG002","value":"-4.75","spread":"0.618"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"-4.76","spread":"0.617"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"-4.77","spread":"0.613"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"-4.77","spread":"0.613"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure","description":"Virologic failure was defined as\n\n* On-treatment virologic failure\n\n  * HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ, while on treatment,\n  * \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment,\n  * HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie nonresponse)\n* Relapse\n\n  * HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":null},{"groupId":"OG001","value":"3.4","spread":null},{"groupId":"OG002","value":"8.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 24 in MELD Score","description":"Model for End-Stage Liver Disease (MELD) scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40; higher scores/increased scores indicate greater severity of disease.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.1","spread":null},{"groupId":"OG001","value":"49.3","spread":null},{"groupId":"OG002","value":"50.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3","spread":null},{"groupId":"OG001","value":"25.3","spread":null},{"groupId":"OG002","value":"21.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"25.3","spread":null},{"groupId":"OG002","value":"27.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Decrease, No Change, or Increase Between Baseline and Posttreatment Week 24 in Child-Pugh-Turcotte (CPT) Score","description":"CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15; higher scores/increased scores indicate greater severity of disease.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9","spread":null},{"groupId":"OG001","value":"53.3","spread":null},{"groupId":"OG002","value":"63.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.5","spread":null},{"groupId":"OG001","value":"37.3","spread":null},{"groupId":"OG002","value":"27.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":null},{"groupId":"OG001","value":"9.3","spread":null},{"groupId":"OG002","value":"8.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":90},"commonTop":["Fatigue","Nausea","Headache","Anaemia","Diarrhoea"]}}}